Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SBP GROUP Discloses 2 Clinical Data Sets for Innovative Drug M701
Recommend 14 Positive 18 Negative 5 |
||||
|
||||
|
SBP GROUP (01177.HK) announced that data from two clinical studies of M701 “CD3/EpCAM Bispecific Antibody”, a national Category 1 innovative drug jointly developed by Chia Tai Tianqing Pharmaceutical (CTTQ), a subsidiary of the Group, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting: the Phase III registrational clinical study in malignant ascites (MA) and the Phase II clinical study in malignant pleural effusion (MPE) associated with non-small cell lung cancer (NSCLC). Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
